Medscape (2/10, Nelson, Subscription Publication) reports researchers in the UK “have identified genetic changes in tumors that could be used to predict whether immunotherapy drugs will be effective in a given patient.” The researchers “found that the number of genetic mutations present in cancer cells was the best predictor of tumor response to immunotherapy with checkpoint inhibitors,” with a higher number tied to a greater likelihood of response. The findings were published in Cell.
